Drugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.
on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.
The company's revenue fell year-over-year due to a sharp, but expected, drop in sales from COVID pill molnupiravir, and rose more than 10% excluding that drug.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Merck Keeps Striking Out on Expanding Its Cancer-Drug JuggernautKeytruda has been a gold mine for Merck—but the cancer drug’s patent is running out, and the company has struck out on many prospective new uses
Weiterlesen »
Supply of prostate cancer drug should increase later this year, drugmaker saysSupply of cancer drug Pluvicto should increase in second half of the year, company says
Weiterlesen »
Bristol-Myers CEO Giovanni Caforio to Leave DrugmakerChief Commercialization Officer Christopher Boerner to take over after Giovanni Caforio retires, the company said.
Weiterlesen »
Merck stock pops premarket after Q1 earnings beatMerck & Co. Inc.’s stock rose 2% premarket Thursday, after the company posted better-than-expected first-quarter earnings and offered guidance that topped...
Weiterlesen »
Meta Platforms stock rallies on results, Mobileye Global stock sinks and other stocks on the moveCaterpillar and Merck & Co’s stock rise after reporting quarterly results.
Weiterlesen »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care. Drugmaker Eli Lilly and Co. reported Thursday that its drug tirzepatide helped people with diabetes who were overweight or had obesity lose up to 16% of their body weight over 17 months in a late-stage trial. For those without the disease, the drug has prompted losses of more than 20% of body weight. Known as Mounjaro for diabetes use, the drug has been used “off label” for weight loss since last year. Lilly is applying for fast-track approval from U.S. regulators and expects a decision this year. Analysts have predicted tirzepatide could become one of the top-selling drugs ever, with annual sales of more than $50 billion.
Weiterlesen »